Observational studyJournal of neurology2016
Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
Observational study in Journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- 2025 Brazilian guidelines for the management of neuromyelitis optica spectrum disorder in adults and children.Arquivos de neuro-psiquiatria · 2025Guideline
- A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disorders.Medicine · 2022Pooled it
- Effectiveness of rituximab in neuromyelitis optica: a meta-analysis.BMC neurology · 2019Pooled it
- Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4-IgG-Positive NMOSD.Annals of clinical and translational neurology · 2026Article
- Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study.CNS drugs · 2025Observational
- Relapses during treatment with monoclonal antibodies targeting B-cells in NMOSD.Journal of neurology · 2025Article
- Relapse risk after rituximab discontinuation in neuromyelitis optica spectrum disorders: a multi-center retrospective cohort study.Journal of neurology · 2025Article
- Long-Term Adverse Events of Rituximab in Multiple Sclerosis Patients, Isfahan, Iran.International journal of preventive medicine · 2025Article
- Decoding paraneoplastic neuromyelitis optica: a multi-omics investigation of tumor-driven T and B cell dynamics.Frontiers in immunology · 2025Review
- A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder.Current neurology and neuroscience reports · 2023Review
- Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study.Neurology and therapy · 2023Article
- B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20.ImmunoTargets and therapy · 2021Review
- Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2.Neurology(R) neuroimmunology & neuroinflammation · 2021Review
- New Therapeutic Landscape in Neuromyelitis Optica.Current treatment options in neurology · 2021Review
- Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.Therapeutic advances in neurological disorders · 2021Article
- Article
- Efficacy and safety of rituximab in patients with refractory neuromyelitis optica spectrum disorders: A prospective observation in Iranian cases.Caspian journal of internal medicine · 2020Article
- Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.Journal of neurology · 2019Article
- Emerging Role of Immunity in Cerebral Small Vessel Disease.Frontiers in immunology · 2018Review
- What's new in neuromyelitis optica? A short review for the clinical neurologist.Journal of neurology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rituximab (RTX) efficacy in NMO is suggested by several case series. No consensus exists on optimal dosing strategies. At present the treatment schedules more frequently used are 375 mg/m2/week iv for 4 weeks (RTX-A) and 1000 mg iv twice, 2 weeks apart (RTX-B). Aim of this study is to confirm RTX efficacy and safety in the treatment of NMO and to evaluate whether a most favourable dosage regimen exists. Data on RTX-treated NMO patients were collected from 13 Italian Hospitals. 73 patients (64 F), were enlisted. RTX-A was administered in 42/73 patients, RTX-B in 31/73. Median follow-up was 27 months (range 7-106). Mean relapse rate in the previous year before RTX start was 2.2 ± 1.3 for RTX-A and 2.3 ± 1.2 for RTX-B. ARR in the first year of treatment was 0.8 ± 0.9 for RTX-A and 0.2 ± 0.4 for RTX-B, in the second year of treatment was 0.9 ± 1.5 for RTX-A and 0.4 ± 0.8 for RTX-B patients (p = 0.001 for the first year, ns (0.09) for the second year). RTX-B was more effective in delaying the occurrence of a relapse (HR 2.2 (95 % IC 1.08-4.53) p = 0.02). Adverse events were described in 19/73 patients (mainly urinary tract and respiratory infections, and infusion reactions). Two deaths were reported in severely disabled patients. Though with the limitations of an observational study, our data support RTX efficacy in NMO and suggest that high dose pulses might be more effective than a more fractioned dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.